1. 皮膚真菌症診断・治療ガイドライン
渡辺晋一ほか： 日本皮膚科学会誌, 119（5）：851-862, 2009
- 2. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies.
Elewski BE, et al.：J Am Acad Dermatol, 68（4）：600-608, 2013
- 3. Transungual delivery of efinaconazole: Its deposition in the nail of onychomysis patients and in vitro fungicidal activity in human nails.
Sakamoto M, et al：. J Drugs Dermatol, 13（7）：1388-1392, 2014
4. Mechanism of action of efinaconazole, a novel triazole antifungal agent.
Tatsumi Y, et al.：Antimicrob Agents Chemother, 57（5）：2405-2409, 2013
- 5. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ, et al：. Antimicrob Agents Chemother, 57（4）： 1610-1616, 2013
- 6. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
Sugiura K, et al.：Antimicrob Agents Chemother, 58（7）：3837-3842, 2014
- 7. In vitro and in vivo assessment of dermatophyte acquired resistance to efinaconazole, a novel triazole antifungal.
Iwata A, et al：. Antimicrob Agents Chemother, 58（8）： 4920-4922, 2014
- 8. エフィナコナゾールの国際共同第III相試験における日本人爪真菌症患者についての有効性と安全性
渡辺晋一ほか:西日本皮膚科, 77（3）： 256-264, 2015（科研製薬との利益相反あり）
ページトップに戻る
MOVIE
